Fatty acid nitroalkenes ameliorate glucose intolerance and pulmonary hypertension in high-fat diet-induced obesity

Cardiovascular Research

Volumn 101, Issue 3, 2014, Pages 352-363

  Kelley, Eric E ^a,b   Baust, Jeff ^b   Bonacci, Gustavo ^a   Golin Bisello, Franca ^a   Devlin, Jason E ^b   St Croix, Claudette M ^b   Watkins, Simon C ^b   Gor, Sonia ^a   Cantu Medellin, Nadiezhda ^b   Weidert, Eric R ^a   Frisbee, Jefferson C ^c   Gladwin, Mark T ^a,b   Champion, Hunter C ^a,b   Freeman, Bruce A ^a,b   Khoo, Nicholas K H ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Inflammation; Nitro fatty acid signalling; Obesity; Pulmonary hypertension; Xanthine Oxidase

Indexed keywords

INFLAMMATION; NITRO-FATTY ACID SIGNALLING; OBESITY; PULMONARY HYPERTENSION; XANTHINE OXIDASE;

ADIPOSE TISSUE; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIET, HIGH-FAT; FATTY ACIDS; GLUCOSE INTOLERANCE; HYPERTENSION, PULMONARY; INSULIN; INSULIN RESISTANCE; MALE; MICE; MICE, INBRED C57BL; OBESITY;

EID: 84894599408     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt341     Document Type: Article

References (42)

1. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005;96:939-949.
2. Sood A. Obesity, adipokines, and lung disease. J Appl Physiol 2010;108:744-753.
3. Summer R, Walsh K, Medoff BD. Obesity and pulmonary arterial hypertension: is adiponectin the molecular link between these conditions? Pulm Circ 2011;1:440-447.
4. Champion HC, Michelakis ED, Hassoun PM. Comprehensive invasive and noninvasive approach to the right ventricle-pulmonary circulation unit: state of the art and clinical and research implications. Circulation 2009;120:992-1007.
5. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation 2004;109:159-165.
6. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006;444:860-867.
7. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011;11:85-97.
8. Price LC, Wort SJ, Perros F, Dorfmüller P, Huertas A, Montani D et al. Inflammation in pulmonary arterial hypertension. Chest 2012;141:210-221.
9. Soon E, Holmes AM, Treacy CM, Doughty NJ, Southgate L, Machado RD et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 2010;122:920-927.
10. Steiner MK, Syrkina OL, Kolliputi N, Mark EJ, Hales CA, Waxman AB. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res 2009;104:236-244.
11. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007;87:315-424.
12. Spiekermann S, Schenk K, Hoeper MM. Increased xanthine oxidase activity in idiopathic pulmonary arterial hypertension. Eur Respir J 2009;34:276.
13. Hoshikawa Y, Ono S, Suzuki S, Tanita T, Chida M, Song C et al. Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia. J Appl Physiol 2001;90:1299-1306.
14. Jankov RP, Kantores C, Pan J, Belik J. Contribution of xanthine oxidase-derived superoxide to chronic hypoxic pulmonary hypertension in neonatal rats. Am J Physiol Lung Cell Mol Physiol 2008;294:L233-L245.
15. Freeman BA, Baker PR, Schopfer FJ, Woodcock SR, Napolitano A, d'Ischia M. Nitro-fatty acid formation and signaling. J Biol Chem 2008;283:15515-15519.
16. Schopfer FJ, Cipollina C, Freeman BA. Formation and signaling actions of electrophilic lipids. Chem Rev 2011;111:5997-6021.
17. Kansanen E, Jyrkkanen HK, Volger OL, Leinonen H, Kivela AM, Hakkinen SK et al. Nrf2-dependent and-independent responses to nitro-fatty acids in human endothelial cells: identification of heat shock response as the major pathway activated by nitro-oleic acid. J Biol Chem 2009;284:33233-33241.
18. Kelley EE, Batthyany CI, Hundley NJ, Woodcock SR, Bonacci G, Del Rio JM et al. Nitro-oleic acid, a novel and irreversible inhibitor of xanthine oxidoreductase. J Biol Chem 2008;283:36176-36184.
19. Khoo NKH, Rudolph V, Cole MP, Golin-Bisllo F, Schopfer FJ, Woodcock SR et al. Activation of vascular endothelial nitric oxide synthase and heme oxygenase-1 expression by electrophilic nitro-fatty acids. Free Radic Biol Med 2010;48:230-239.
20. Xu X, Zhao L, Hu X, Zhang P, Wessale J, Bache R et al. Delayed treatment effects of xanthine oxidase inhibition on systolic overload-induced left ventricular hypertrophy and dysfunction. Nucleosides Nucleotides Nucleic Acids 2010;29: 306-313.
21. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER et al.Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005;11:214-222.
22. Champion HC, Georgakopoulos D, Takimoto E, Isoda T, Wang Y, Kass DA. Modulation of in vivo cardiac function by myocyte-specific nitric oxide synthase-3. Circ Res 2004;94: 657-663.
23. Khoo NKH, Cantu-Medellin N, Devlin JE, St. Croix CM, Watkins SC, Fleming AM et al. Obesity-induced tissue free radical generation: an in vivo immuno-spin trapping study. Free Radic Biol Med 2012;52:2312-2319.
24. Ren J. Leptin and hyperleptinemia-from friend to foe for cardiovascular function. J Endocrinol 2004;181:1-10.
25. Dalle-Donne I, Rossi R, Giustarini D, Milzani A, Colombo R. Protein carbonyl groups as biomarkers of oxidative stress. Clin Chim Acta 2003;329:23-38.
26. Haque AK, Gadre S, Taylor J, Haque SA, Freeman D, Duarte A. Pulmonary and cardiovascular complications of obesity: an autopsy study of 76 obese subjects. Arch Pathol Lab Med 2008;132:1397-1404.
27. Burger CD, Foreman AJ, Miller DP, Safford RE, McGoon MD, Badesch DB. Comparison of body habitus in patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term PAH disease management with normative values from the national health and nutrition examination survey. Mayo Clin Proc 2011;86: 105-112.
28. Hassoun P, Yu F-S, Cote C, Zulueta J, Sawhney R, Skinner KA et al. Upregulation of xanthine oxidase by lipopolysaccharide, interleukin-1, and hypoxia. Am J Respir Crit Care Med 1998;158:299-305.
29. Malik UZ, Hundley NJ, Romero G, Radi R, Freeman BA, TarpeyMMet al. Febuxostat inhibition of endothelial-bound XO: implications for targeting vascular ROS production. Free Radic Biol Med 2011;51:179-184.
30. Ohtsubo T, Rovira II, StarostMF, Liu C, FinkelT. Xanthine oxidoreductase is an endogenous regulator of cyclooxygenase-2. Circ Res 2004;95:1118-1124.
31. Coles B, Bloodsworth A, Clark SR, Lewis MJ, Cross AR, Freeman BA et al. Nitrolinoleate inhibits superoxide generation, degranulation, and integrin expression by human neutrophils. Circ Res 2002;91:375-381.
32. Quarck R, Nawrot T, Meyns B, Delcroix M. C-reactive protein: a new predictor of adverse outcome in pulmonary arterial hypertension. J Am Coll Cardiol 2009;53: 1211-1218.
33. Nakagawa Y, Kishida K, Kihara S, Funahashi T, Shimomura I. Adiponectin ameliorates hypoxia-induced pulmonary arterial remodeling. Biochem Biophys Res Commun 2009; 382:183-188.
34. Weng M, Raher MJ, Leyton P, Combs TP, Scherer PE, Bloch KD et al. Adiponectin decreases pulmonary arterial remodeling in murine models of pulmonary hypertension. Am J Respir Cell Mol Biol 2011;45:340-347.
35. Hansmann G, Wagner RA, Schellong S, Perez VA, Urashima T, Wang L et al. Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. Circulation 2007;115: 1275-1284.
36. Huertas A, Tu L, Gambaryan N, Girerd B, Perros F, MontaniDet al. Leptin and regulatory T-lymphocytes in idiopathic pulmonary arterial hypertension. Eur Respir J 2012;40: 895-904.
37. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004; 114:1752-1761.
38. Baldwin W, McRae S, Marek G, Wymer D, Pannu V, Baylis C et al. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes 2011;60: 1258-1269.
39. Zamanian RT, Hansmann G, Snook S, Lilienfeld D, Rappaport KM, Reaven GM et al. Insulin resistance in pulmonary arterial hypertension. Eur Respir J 2009;33:318-324.
40. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;335:609-616.
41. Taraseviciute A, Voelkel NF. Severe pulmonary hypertension in postmenopausal obese women. Eur J Med Res 2006;11:198-202.
42. Robbins IM, Newman JH, Johnson RF, Hemnes AR, Fremont RD, Piana RN et al. Association of the metabolic syndrome with pulmonary venous hypertension. Chest 2009;136: 31-36.